United States: Final HIPAA / HITECH Regulations Published: Revisions That Impact Research Activities

Last Updated: January 29 2013
Article by Jennifer J. Daniels

Healthcare

The long-awaited HIPAA/HITECH Final Rule is out! The Final Rule - titled Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification Rules under the Health Information Technology for Economic and Clinical Health Act and the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules - includes several provisions that impact research activities, most of which are consistent with the proposed rule published on July 14, 2010. And, while in many ways the Final Rule makes things harder for Covered Entities and Business Associates, research involving the use of Protected Health Information just got a little easier.

Compound Authorizations

As those involved in human subject research know, from the beginning, the Privacy Rule created enormous headaches for researchers because it prohibited Covered Entities from combining an authorization for research that conditions research-related treatment upon the signing of the authorization (conditioned research) with another authorization for research that does not condition treatment upon the signing of an authorization (unconditioned research). So, for example, an authorization to participate in a clinical trial for a study drug could not be combined with an authorization to bank data and tissue samples or to participate in an optional sub-study.

The Final Rule adopts the proposal to amend 45 C.F.R. § 164.508(b)(3)(i) and (iii) to allow a Covered Entity to combine conditioned and unconditioned authorizations for research, provided that the compound authorization (1) clearly differentiates between the conditioned and unconditioned research components, and (2) clearly allows the individual the option to opt-in to the unconditioned research activities. The Final Rule permits the use of compound authorizations for any type of research activities, including optional sub-studies, and secondary future use of data (to the extent secondary future use is permitted by the Final Rule as discussed below), except where the research involves the use and/or disclosure of psychotherapy notes.

The Final Rule does not allow an authorization to include an option to opt-out of the unconditioned research activities. So, for example, the authorization cannot say "check here if you do not want your data provided to the biospecimens bank." In the commentary to the Final Rule, the Department of Health and Human Services (HHS) approves of three methods proposed by the Secretary's Advisory Committee on Human Research Protections (SACHRP) to obtain the necessary opt-in for unconditioned research activities: (1) a combined consent / authorization form for a clinical trial and optional banking component, with a check-box for the individual to have the choice to opt-in to the optional banking component, and one signature; (2) a combined consent / authorization form for a clinical trial and optional banking component, with one signature for the clinical trial and another signature to indicate the individual agrees to the optional banking component; and (3) a combined consent / authorization form for a clinical trial and optional banking component, with a check box to opt-in to the banking component, one signature, but with the detailed information about the banking presented in a separate brochure or information sheet referenced directly in the consent / authorization form. HHS clarifies that, for the third approach, the brochure or information sheet must be incorporated by reference into the authorization / consent form such that it is considered part of the form. In addition, if the brochure or information sheet includes any of the required elements of the authorization, and the authorization has not been altered by an IRB approved waiver, then the brochure / information sheet must be made available to potential research participants before they are asked to sign the authorization. Finally, in such cases, a Covered Entity must keep not only the signed authorization, but also a copy of the brochure or information sheet, in order to comply with documentation requirements under the Privacy Rule.

HHS explains in the preamble that Covered Entities are permitted but are not required to create compound authorizations for conditioned and unconditioned research activities. So, researchers may choose to use separate authorization forms. HHS makes clear that Covered Entities and researchers have flexibility in the methods used to distinguish the conditioned and unconditioned research activities and to provide the individual with a clear opportunity to opt-in to the unconditioned portions.

In response to a comment asking whether a portion of the compound authorization can be revoked without revoking the entire authorization, HHS clarifies that, where it is clear that an individual is revoking only part of a compound authorization, then the researchers can proceed accordingly. If it is not clear that only a specific part of the compound authorization is being revoked, then the researchers must either obtain written clarification from the participant or the entire authorization must be treated as revoked.

Authorization for Future Research Uses

Since its initial promulgation, HHS has interpreted Section 164.508(c)(1)(iv) of the Privacy Rule to require that authorizations for research be study specific. In other words, HHS took the position that a Covered Entity could not obtain an authorization from an individual that allowed PHI to be used for future, unspecified research, but rather each authorization had to specify the study for which PHI would be used and disclosed. As one scientist at a pharmaceutical company once put it to me, Ford Motor Company is allowed to take data it obtained from the last car it built to build a better car, but HIPAA prevents pharmaceutical manufacturers from using data collected in one study to build a better study the next time. So, to comply with the Privacy Rule, research sponsors jumped through hoops to be able to use PHI collected from one study for additional purposes, including forever tinkering with informed consent language to try to provide as specific a description as possible while still allowing for some flexibility to conduct additional research in the future, and adding broad data use language to clinical trial agreements to allow for the use of a limited data set in future research studies.

Now, HHS has modified the requirement that research authorizations be study specific. This modification does not make any changes to the authorization requirements in the regulations themselves - a HIPAA authorization for future research must still address each of the core elements required by § 164.508(c). But, in the preamble to the Final Rule, HHS says that it no longer interprets the "purpose" provision in § 164.508(c)(1)(iv) as requiring that an authorization be study specific. In order to satisfy the requirement that an authorization include a description of each purpose of the requested use or disclosure, HHS explains that an authorization for future research must adequately describe such purposes such that it would be reasonable for the individual to expect that his or her PHI could be used or disclosed for such future research. This could include specific statements with respect to sensitive research to the extent such research is contemplated. HHS clarifies that its intent is to give Covered Entities, researchers and IRBs flexibility in determining what adequately describes future research purposes.

It is important to note that HHS is not permitting authorizations to simply state that PHI may be used for future, unspecified research. HHS has aimed to bring the requirements for specificity under HIPAA in line with what is required by the Common Rule, which is to seek informed consent for future research so long as the future research uses are described in sufficient detail to allow an informed consent.

Also, HHS explains in the preamble to the Final Rule that there is no prohibition against the description of the information to be used or disclosed including PHI created after the end of the main study (e.g., allowing for disclosure of "your future medical records relating to a particular disease / condition").

Sale of PHI

Section 13405(d)(1) of the HITECH Act prohibits a Covered Entity or Business Associate from receiving direct or indirect remuneration in exchange for the disclosure of PHI unless the Covered Entity or Business Associate has obtained an individual's authorization pursuant to Section 164.508 that states whether the PHI can be further exchanged for remuneration by the entity receiving the information. The statute provides for several exceptions from the prohibition, which the Final Rule adopts, but HHS makes certain clarifications as to its scope. HHS creates a new defined term in the final rule for "sale of protected health information," which sale requires specific authorization. The defined term explicitly excludes disclosures for research purposes where the only remuneration received by the Covered Entity or Business Associate is a reasonable, cost-based fee to cover the cost to prepare and transmit the PHI for such purposes.

HHS does not consider a "sale of PHI" to encompass payments that a Covered Entity may receive in the form of grants, or contracts or other arrangements to perform research activities, because any provision of PHI to the payer is a byproduct of the service being provided to the payer by the Covered Entity. HHS explains, therefore, that the payment by a research sponsor to a Covered Entity to conduct a research study is not considered a "sale of PHI," even if the research results disclosed to the sponsor include PHI. Similarly, the receipt of a grant or funding from a government agency to conduct a research program is not a sale of PHI, even if some PHI is released to the government agency. But, a disclosure of PHI by a Covered Entity to an outside researcher, where the outside researcher is conducting research in exchange for remuneration and no services are being performed by the Covered Entity in exchange for the payment, would be considered a "sale of PHI," unless the only remuneration received by the Covered Entity is a reasonable, cost-based fee to cover the cost to prepare and transmit the data for such purposes. In determining whether the fee is reasonable, the Covered Entity can consider direct and indirect costs, including labor, materials and supplies for generating, storing, retrieving and transmitting PHI, related costs and overhead. However, HHS is clear that fees charged to incur a profit from the disclosure of PHI are not allowed without authorization.

HHS explains in the preamble to the Final Rule that ongoing research projects under existing authorizations, waivers of authorization or data use agreements are grandfathered such that the Covered Entity need not obtain a new authorization if there is a disclosure involved that amounts to a "sale of PHI." HHS goes on to say that the Covered Entity or Business Associate, not the IRB, is responsible for determining whether any fees paid to the Covered Entity or Business Associate in exchange for PHI cover only the Covered Entity's or Business Associate's costs to prepare and transmit PHI for research. Based on this discussion in the preamble - which indicates that an IRB is not in a position to determine whether a fee paid to a researcher is "a reasonable, cost-based fee to cover the cost to prepare and transmit the data" - it is unclear whether an IRB is able to waive the need for an authorization under § 164.512(i) for research where there is payment made for the disclosure of PHI. It may be that an IRB would grant a waiver of the need for an authorization if the Covered Entity certifies that any payment is a reasonable, cost based fee to cover the cost to prepare and transmit the data.

HHS refuses in the Final Rule to exclude a Limited Data Set from the prohibition on a sale of PHI. A Covered Entity may continue to use and/or disclose a Limited Data Set in accordance with an existing Data Use Agreement until the Data Use Agreement is renewed or is modified or until one (1) year from the compliance date of the Final Rule, whichever is earlier, even if the disclosure would otherwise require authorization because of remuneration paid for PHI.

Effective Date

The Final Rule is effective March 26, 2013. Covered Entities, Business Associates and Subcontractors will have 180 days beyond the effective date to come into compliance, which 180 days expire on September 23, 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Jennifer J. Daniels
Similar Articles
Relevancy Powered by MondaqAI
Drinker Biddle & Reath LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Drinker Biddle & Reath LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions